Ubiquitin, E6-AP, and their role in p53 inactivation

Pharmacology and Therapeutics

Volumn 78, Issue 3, 1998, Pages 129-139

  Scheffner, Martin ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Carcinogenesis; E6 AP; p53; Protein degradation; Ubiquitin

Indexed keywords

ONCOPROTEIN; PROTEASOME; PROTEIN P53; UBIQUITIN;

CARCINOGENESIS; GENE ACTIVATION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STABILITY; REVIEW; WART VIRUS;

CYSTEINE ENDOPEPTIDASES; HUMANS; LIGASES; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 0031780665     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00003-5     Document Type: Review

References (129)

1. Albrecht U., Sutcliffe J.S., Cattanach B.M., Beechey C.V., Armstrong D., Eichele G., Beaudet A.L. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat. Genet. 17:1997;75-78.
2. Attardi L.D., Lowe S.W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:1996;3693-3701.
3. Barbosa M.S. The oncogenic role of human papillomavirus proteins. Crit. Rev. Oncog. 7:1996;1-18.
4. Bates S., Vousden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1996;12-18.
5. Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene. 14:1997;595-602.
6. Bos T.J., Monteclaro F.S., Mitsunobu F., Ball A.R., Chang C.H.W., Nishimura T., Vogt P.K. Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modifications in coding and noncoding sequences. Genes Dev. 4:1990;1677-1687.
7. Bottger A., Bottger V., Garcia-Echeverria C., Chene P., Hochkeppel H.K., Sampson W., Ang K., Howard S.F., Picksley S.M., Lane D.P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269:1997;744-756.
8. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
9. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
10. Chen P., Johnson P., Sommer T., Jentsch S., Hochstrasser M. Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MATα2 repressor. Cell. 74:1993;357-369.
11. Chen X., Ko L.J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:1996;2438-2451.
12. Chen Z., Hagler J., Palombella V.J., Melandri F., Scherer D., Ballard D., Maniatis T. Signal-induced site-specific phosphorylation targets IkappaB alpha to the ubiquitin-proteasome pathway. Genes Dev. 9:1995;1586-1597.
13. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex. understanding tumorigenic mutations Science. 265:1994;346-355.
14. Chowdary D.R., Dermody J.J., Jha K.K., Ozer H.L. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14:1994;1997-2003.
15. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
16. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie R.G. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
17. Demers G.W., Halbert C.L., Galloway D. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology. 198:1994;169-174.
18. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
19. Donehower L.A. The p53-deficient mouse. a model for basic and applied cancer studies Semin. Cancer Biol. 7:1996;269-278.
20. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
21. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer E., Kinzler K.W., Vogelstein B. WAF-1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
22. Fiscella M., Ullrich S.J., Zambrano N., Shields M.T., Lin D., Lees-Miller S.P., Anderson C.W., Mercer W.E., Appella E. Mutatation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene. 8:1993;1519-1528.
23. Foster S.A., Demers G.W., Etscheid B.G., Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin-D-induced growth arrest. J. Virol. 68:1994;5698-5705.
24. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
25. Fu L., Benchimol S. Participation of the human p53 3′UTR in translational repression and activation following γ-irradiation. EMBO J. 13:1997;4117-4125.
26. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287:1996;77-102.
27. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
28. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
29. Gronostajski R.M., Goldberg A.L., Pardee A.B. Energy requirement for degradation of tumor-associated protein p53. Mol. Cell. Biol. 4:1984;442-448.
30. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines. updated compilation and future prospects Nucl. Acids Res. 25:1997;151-157.
31. Halevy O., Hall A., Oren M. Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines. effects of protein sequence and intracellular environment Mol. Cell. Biol. 9:1989;3385-3392.
32. Hall P.A., Lane D.P. Tumor suppressors. a developing role for p53? Curr. Biol. 7:1997;R144-R147.
33. Hansen R., Oren M. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7:1997;46-51.
34. Hansen S., Midgley C.A., Lane D.P., Freeman B.C., Morimoto R.I., Hupp T.R. Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70. J. Biol. Chem. 271:1996;30922-30928.
35. Harper J.W., Adami G.R., Wei N., Keyomarski K., Elledge S.J. The p21 CDK-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
36. Haupt Y., Rowan S., Shaulian E., Vousden K.H., Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:1995;2170-2183.
37. Haupt Y., Barak Y., Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1996;1596-1606.
38. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
39. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55:1995;4420-4424.
40. Hermeking H., Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 265:1994;2091-2093.
41. Hershko A. Mechanisms and regulation of ubiquitin-mediated cyclin degradation. Adv. Exp. Med. Biol. 389:1996;221-227.
42. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol. 7:1995;215-223.
43. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30:1996;405-439.
44. Hochstrasser M., Varshavsky A. In vivo degradation of a transcriptional regulator. the yeast α2 repressor Cell. 61:1990;697-708.
45. Hoppe-Seyler, F. and Scheffner, M. (1997) The E6 oncoprotein. In: Papillomaviruses in Human Cancer: The Role of the E6 and E7 Oncoproteins, Molecular Biology Intelligence Unit, pp. 71-102, Tommasino, M. (ed.) Landes Bioscience, Austin.
46. Hubbert N.L., Sedman S.A., Schiller J.T. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J. Virol. 66:1992;6237-6241.
47. Huibregtse J.M., Scheffner M. Mechanisms of tumor suppressor protein inactivation by the human papillomavirus E6 and E7 oncoproteins. Semin. Virol. 5:1994;357-367.
48. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 and 18. EMBO J. 10:1991;4129-4135.
49. Huibregtse J.M., Scheffner M., Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 13:1993;775-784.
50. Huibregtse J.M., Scheffner M., Beaudenon S., Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA. 92:1995;2563-2567.
51. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 75:1992;875-886.
52. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
53. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:1997;558-570.
54. Jentsch S., Schlenker S. Selective protein degradation. a journey's end within the proteasome Cell. 82:1995;881-884.
55. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208.
56. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.-J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-telangiectasia. Cell. 71:1992;587-597.
57. Kessis T.D., Slebos R.J., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., Lorincz A.T., Hedrick L., Cho K.R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA. 90:1993;3988-3992.
58. King R.W., Deshaies R.J., Peters J.M., Kirschner M.W. How proteolysis drives the cell cycle. Science. 274:1996;1652-1659.
59. Kishino T., Lalande M., Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat. Genet. 15:1997;70-73.
60. Ko L.J., Prives C. p53. puzzle and paradigm Genes Dev. 10:1996;1054-1072.
61. Kornitzer D., Raboy B., Kulka R.G., Fink G.R. Regulated degradation of the transcription factor Gcn4. EMBO J. 13:1994;6021-6030.
62. Kubbutat M.H., Jones S.N., Vousden K.H. Proteolytic cleavage of human p53 by calpain. a potential regulator of protein stability Mol. Cell. Biol. 17:1997;460-468. a.
63. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303. b.
64. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell-cycle checkpoint determinant following radiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
65. Kumar S., Kao W.H., Howley P.M. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J. Biol. Chem. 272:1997;13548-13554.
66. Lamph W.W., Wamsley P., Sassone-Corsi P., Verma I.M. Induction of the oncogene jun/AP-1 by serum and TPA. Nature. 334:1988;629-631.
67. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
68. Lanker S., Valdivieso M.H., Wittenburg C. Rapid degradation of the G1 cyclin Cln2 induced by CDK-dependent phosphorylation. Science. 271:1996;1597-1601.
69. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234.
70. Lechner M.S., Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:1994;4262-4273.
71. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
72. Li X., Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70:1996;4509-4516. a.
73. Li X., Coffino P. Identification of a region of p53 that confers liability. J. Biol. Chem. 271:1996;4447-4451. b.
74. Lin W.C., Desiderio S. Regulation of V(D)J recombination activator protein RAG-2 by phosphorylation. Science. 260:1993;953-959.
75. Linke S.P., Clarkin K.C., Di Leonardo A., Tsou A., Wahl G.M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:1996;934-947.
76. Lowe S.W., Ruley H.E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7:1993;535-545.
77. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
78. Lutzker S.G., Levine A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med. 2:1996;804-810.
79. Maki C.G., Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17:1997;355-363.
80. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
81. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1984;1689-1694.
82. Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.J., Jiang Y.H., Benton C.S., Rommens J.M., Beaudet A.L. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (Ube3a) in Angelman syndrome. Nat. Genet. 15:1997;74-77.
83. Mayo L.D., Berberich S.J. Wild-type p53 is unable to activate the mdm-2 gene during F9 cell differentiation. Oncogene. 13:1996;2315-2321.
84. Medcalf E.A., Milner J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene. 8:1993;2847-2851.
85. Molinari M., Milner J. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene. 10:1995;1849-1854.
86. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer. mutation and nuclear exclusion Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
87. Moll U.M., LaQuaglia M., Bernard J., Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4407-4411.
88. Momand J., Zambetti G.P. Mdm-2. "Big brother" of p53 J. Cell. Biochem. 64:1997;343-352.
89. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
90. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
91. Morgan I.M., Asano M., Havarstein L.S., Ishikawa H., Hiiragi T., Ito Y., Vogt P.K. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication. Oncogene. 8:1993;1135-1140.
92. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:1995;4442-4449.
93. Neil J.C., Cameron E.R., Baxter E.W. p53 and tumour viruses. catching the guardian off-guard Trends Microbiol. 5:1997;115-120.
94. Nevels M., Rubenwolf S., Spruss T., Wolf H., Dobner T. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Proc. Natl. Acad. Sci. USA. 94:1997;1206-1211.
95. Nishizawa M., Okazaki K., Furuno N., Watanabe N., Sagata N. The "second codon rule" and autophosphorylation govern the stability and activity of Mos during the meiotic cell cycle in Xenopus oocytes. EMBO J. 11:1992;2433-2446.
96. Nuber U., Schwarz S., Kaiser P., Schneider R., Scheffner M. Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-f1) and characterization of their interaction with E6-AP and RSP5. J. Biol. Chem. 271:1996;2795-2800.
97. Okazaki K., Sagata N. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J. 14:1995;5048-5059.
98. Okazaki K., Nishizawa M., Furuno M., Yasuda H., Sagata N. Differential occurence of CSF-like activity and transforming activity of Mos during cell cycle in fibroblasts. EMBO J. 11:1992;2447-2456.
99. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.I., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
100. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
101. Oren M., Reich N.C., Levine A.J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2:1982;443-449.
102. Pan H., Griep A.E. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice. implications for tumor suppressor gene function in development Genes Dev. 8:1994;1285-1299.
103. Pan H., Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9:1995;2157-2169.
104. Pariat M., Carillo S., Molinari M., Salvat C., Debussche L., Bracco L., Milner J., Piechaczyk M. Proteolysis by calpains. a possible contribution to degradation of p53 Mol. Cell. Biol. 17:1997;2806-2815.
105. Piette J., Neel H., Marechal V. Mdm2. keeping p53 under control Oncogene. 15:1997;1001-1010.
106. Pim D., Storey A., Thomas M., Massimi P., Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene. 9:1994;1869-1876.
107. Puthenveettil J.A., Frederickson S.M., Reznikoff C.A. Apoptosis in human papillomavirus16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene. 13:1996;1123-1131.
108. Querido E., Marcellus R.C., Lai A., Charbonneau R., Teodoro J.G., Ketner G., Branton P.E. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:1997;3788-3798.
109. Reich N.C., Oren M., Levine A.J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3:1983;2143-2150.
110. Reznikoff C.A., Belair C., Savelieva E., Zhai Y., Pfeifer K., Yeager T., Thompson K.J., DeVries S., Bindley C., Newton M.A., Sekhon G., Waldman F. Long-term genome stability and minimal genotypic and phenotypic alterations in human HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 8:1994;2227-2240.
111. Rolfe M., Beer-Romero P., Glass S., Eckstein J., Berdo I., Theodoras A., Pagano M., Draetta G. Reconstitution of p53-ubiquitinylation reactions from purified components. the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6ap) Proc. Natl. Acad. Sci. USA. 92:1995;3264-3268.
112. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
113. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-Ap complex functions as a ubiquitin-protein ligase complex in the ubiquitination of p53. Cell. 75:1993;495-505.
114. Scheffner M., Huibregtse J.M., Howley P.M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA. 91:1994;8797-8801.
115. Scheffner M., Nuber U., Huibregtse J.M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 373:1995;81-83.
116. Scheffner, M., Smith, S. and Jentsch, S. (1998) The ubiquitin-conjugation system. In: Ubiquitin and the Biology of the Cell, pp. 65-98, Peters, J.-M., Harris, J. R. and Finley, D. (eds.) Plenum Publishing Corp., New York and London.
117. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
118. Smith S.E., Koegl M., Jentsch S. Role of the ubiquitin/proteasome system in regulated protein degradation in Saccharomyces cerevisiae. Biol. Chem. 377:1996;437-446.
119. Spitkovsky D., Aengeneyndt F., Braspenning J., von Knebel Doeberitz M. p53-independent regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene. 13:1996;1027-1036.
120. Steegenga W.T., van der Eb A.J., Jochemsen A.G. How phosphorylation regulates the activity of p53. J. Mol. Biol. 263:1996;103-113.
121. Sugrue M.M., Shin D.Y., Lee S.W., Aaronson S.A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA. 94:1997;9648-9653.
122. Sun X., Shimizu H., Yamamoto K. Identification of a novel p53 promoter element involved in genotoxic stress-inducible 53 gene expression. Mol. Cell. Biol. 15:1995;4489-4496.
123. Treier M., Staszewski L.M., Bohmann D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the δ domain. Cell. 78:1994;787-798.
124. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
125. White A.E., Livanos E.M., Tlsty T.D. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8:1994;666-677.
126. Xu Y., Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10:1996;2401-2410.
127. Yaglom J., Linskens M.H., Sadis S., Rubin D.M., Futcher B., Finley D. p34Cdc28-mediated control of Cln3 cyclin degradation. Mol. Cell. Biol. 15:1995;731-741.
128. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta. 1288:1996;F55-F78.
129. zur Hausen H., de Villiers E.M. Human papillomaviruses. Annu. Rev. Microbiol. 48:1994;427-447.